ReviewDrugs2018
Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm".
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combined Metabolomics and Network Pharmacology to Reveal Anti-Diabetic Mechanisms and Potential Pharmacological Components ofPlants (Basel, Switzerland) · 2025Article
- Investigation of the Pharmacodynamic Components ofInternational journal of molecular sciences · 2024Article
- Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023Review
- Neuropsychiatric disorders in patients with heart failure: not to be ignored.Heart failure reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Results from recent cardiovascular outcome trials have ushered in a new era in the management of type 2 diabetes mellitus, moving from a focus on glycemic control to the cardiovascular safety of antihyperglycemic agents. Several new antihyperglycemic drugs have been shown to exert either neutral or cardioprotective effects in patients with diabetes. Among them, the sodium-glucose co-transporter-2 (SGLT-2) inhibitors (gliflozins) and selected agents from the incretin mimetics or enhancers, such as the glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins), appear to confer cardiovascular safety and/or protection in patients with underlying, or at high risk for, cardiovascular disease. Metformin remains the standard first-line drug treatment for patients with diabetes because of its established effectiveness and cardiovascular safety. However, this initial drug therapy may not prove adequate as this disease appears to be progressive with a decline in function of the pancreatic beta cells, necessitating the addition of other agents to better control rising glucose levels. With the advent of several new classes of antihyperglycemic drugs and the completion of their respective cardiovascular outcome trials, the therapeutic armamentarium against this disease pandemic appears to be greatly expanding and moving closer to the direction of the Hippocratic aphorism "Do Good or Do No Harm". In this review, we discuss all these issues and summarize the contemporary literature on cardiovascular safety and outcomes of the available glucose-lowering agents.
Indexed as
Identifiers
30251174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.